首页> 外文OA文献 >Prognostic Factors of Second and Third Line Chemotherapy Using 5-FU with Platinum, Irinotecan, and Taxane for Advanced Gastric Cancer

【2h】

Prognostic Factors of Second and Third Line Chemotherapy Using 5-FU with Platinum, Irinotecan, and Taxane for Advanced Gastric Cancer

机译：5-FU联合铂，伊立替康和紫杉烷联合二线和三线化疗对晚期胃癌的预后因素

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Park, Ji Soo; Lim, Jae Yun; Park, Seung Kyo; Kim, Min Kyung; Ko, Hee Sung; Yoon, Sun Och; Kim, Jong Won; Choi, Seung Ho; Cho, Jae Yong;
展开▼
作者单位

展开▼
年度 2011
总页数
原文格式 PDF
正文语种 {"code":"en","name":"English","id":9}
中图分类

相似文献

外文文献
中文文献
专利

1. 6535 A phase II study of biweekly chemotherapy with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) in patients with advanced gastric cancer after failure of prior chemotherapy including taxane, fluoropyrimidine, and platinum [J] . M.Kang, B.Ryoo, M.Ryu, European Journal of Cancer Supplements . 2009,第2期

机译：6535一项对伊立替康，5-氟尿嘧啶和亚叶酸钙（FOLFIRI）进行的双周化学疗法在先前化疗失败的晚期胃癌患者（包括紫杉烷，氟嘧啶和铂）中进行的双周化学治疗的II期研究
2. 6535 A phase II study of biweekly chemotherapy with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) in patients with advanced gastric cancer after failure of prior chemotherapy including taxane, fluoropyrimidine, and platinum [J] . M.Kang, B.Ryoo, M.Ryu, European Journal of Cancer Supplements . 2009,第2期

机译：6535一项对伊立替康，5-氟尿嘧啶和亚叶酸钙（FOLFIRI）进行的双周化学疗法在先前化疗失败的晚期胃癌患者（包括紫杉烷，氟嘧啶和铂）中进行的双周化学治疗的II期研究
3. Irinotecan combined with 5-fluorouracil and leucovorin third-line chemotherapy after failure of fluoropyrimidine, platinum, and taxane in gastric cancer: Treatment outcomes and a prognostic model to predict survival [J] . KangE.J., ImS.-A., OhD.-Y., Gastric cancer: official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association . 2013,第4期

机译：氟嘧啶，铂和紫杉烷治疗胃癌失败后，伊立替康联合5-氟尿嘧啶和亚叶酸三线化疗：治疗结果和预测生存率的预后模型
4. Efficacy of combination chemotherapy with docetaxel and irinotecan as first- or second-line treatment for advanced gastric cancer [C] . K. Sugiyama, A. Ishikawa, T. Watanabe International Gastric Cancer Congress . 2009

机译：组合化疗与多西紫杉醇和伊替康的疗效，作为晚期胃癌的第一或二线治疗
5. Treatment Patterns and Cost-Effectiveness of Chemotherapy Treatments among Advanced Gastric Cancer Patients [D] . Haag, Austin Jade. 2017

机译：晚期胃癌患者化学疗法的治疗模式和成本效益
6. Prognostic Factors of Second and Third Line Chemotherapy Using 5-FU with Platinum Irinotecan and Taxane for Advanced Gastric Cancer [O] . Ji Soo Park, Jae Yun Lim, Seung Kyo Park, 2011

机译：5-FU联合铂伊立替康和紫杉烷联合二线和三线化疗对晚期胃癌的预后因素
7. 5 fluorouracil, leucovorin, and irinotecan (FOLFIRI) as a third-line chemotherapy treatment in metastatic gastric cancer, after failure of fluoropyrimidine, platinum, anthracycline, and taxane [O] . Gokmen Umut Erdem, Yakup Bozkaya, Nuriye Yıldırım Özdemir, 2017

机译：5氟尿嘧啶，白杨素和伊替替康（Folfiri）作为转移性胃癌中的第三线化疗治疗，氟嘧啶失败后，铂，蒽环素和紫杉烷后

Prognostic Factors of Second and Third Line Chemotherapy Using 5-FU with Platinum, Irinotecan, and Taxane for Advanced Gastric Cancer

著录项

相似文献

相关主题

期刊订阅